BILINSKY IGOR 4

What Happened

• Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), had 8,790 restricted stock units (RSUs) vest/convert to common stock on June 1, 2026. Of those, 4,473 shares were withheld by the issuer to satisfy mandatory tax withholding at $3.96 per share (total value $17,713). The vesting resulted in a net delivery of 4,317 shares to Bilinsky (8,790 vested minus 4,473 withheld).
• This was not an open-market sale; the 4,473-share disposition reflects share withholding to cover taxes (cashless/withholding) rather than a sale for cash.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03.
• Vesting/conversion: 8,790 RSUs converted to common stock (reported as derivative exercise/conversion).
• Tax withholding: 4,473 shares withheld at $3.96 each = $17,713 (footnote indicates withholding by issuer, not open-market sale).
• Net shares received by insider: 4,317 common shares.
• Additional notes from filing: each RSU equals one share; remaining RSUs from the March 1, 2024 grant will vest in equal quarterly installments.
• Filing appears timely (reported two days after the transaction).

Context

• RSU vesting and share-withholding for taxes is routine compensation administration and doesn’t necessarily signal buying or selling intent. Here the conversion of RSUs to stock and the withholding to satisfy taxes is effectively a cashless transaction rather than a market sale.
• The filing includes a derivative line removing the RSU entitlement (standard when RSUs convert to common stock).